OT: TPST , also of note on Stoccktwits:
"A number of institutional investors and hedge funds have recently made changes to their positions in TPST. Ikarian Capital LLC lifted its stake in Tempest Therapeutics by 897.1% in the first quarter. Ikarian Capital LLC now owns 1,348,021 shares of the company’s stock valued at $1,617,000 after acquiring an additional 1,212,828 shares during the last quarter. Monashee Investment Management LLC bought a new position in shares of Tempest Therapeutics in the first quarter valued at about $600,000. Renaissance Technologies LLC raised its position in shares of Tempest Therapeutics by 66.0% in the first quarter. Renaissance Technologies LLC now owns 924,801 shares of the company’s stock valued at $1,110,000 after purchasing an additional 367,693 shares during the period. Barclays PLC raised its position in shares of Tempest Therapeutics by 355.7% in the fourth quarter."
" Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARa, respectively. Both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. Tempest is headquartered in South San Francisco and supported by notable healthcare investors."
News 
Market Data 
Discover 
